# **Special Issue**

# **Novel Anti-proliferative Agents**

## Message from the Guest Editor

Cancer is one of the most widely spread and complex forms of disease, cancer cells being distinguished from healthy cells for their altered proliferation and survival. In the past three decades, only the National Cancer Institute (NCI) has screened millions of small molecules for potential anticancer activity. Despite a number of conventional cytotoxic approaches having been developed, their limited effectiveness, in accordance with the heterogeneity of cancer cells, prompts the constant search for novel natural or synthetic compounds with growth inhibition or tumor cell activity killing properties. This *Pharmaceuticals* journal Special Issue invites both reviews and original articles regarding basic, preclinical and clinical studies on antiproliferative chemical entities. I look forward to receiving your contribution.

### **Guest Editor**

Prof. Dr. Valentina Onnis

Department of Life and Environmental Sciences, Unit of Pharmaceutical, Pharmacological and Nutraceutical Sciences, University of Cagliari, University Campus, I-09042 Monserrato, Italy

## Deadline for manuscript submissions

closed (20 May 2023)



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/101269

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





## **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

